科鲁斯制药控股有限公司美股招股说明书(2025-10-30版)

Subject to completion, dated October 30, 2025 PRELIMINARY PROSPECTUS SUPPLEMENT(To Prospectus dated March 20, 2024) Shares of Common Stock Pre-Funded Warrants to PurchaseShares of Common Stock Shares of Common Stock Underlying the Pre-Funded Warrants Corbus Pharmaceuticals Holdings, Inc. We are offeringshares of our common stock, and, in lieu of shares of common stock to investors that so choose, pre-fundedwarrants to purchaseshares of our common stock, or the “pre-funded warrants” (and the shares of common stock issuable fromtime to time upon exercise of each of the pre-funded warrants). The public offering price is $per share. The pre-fundedwarrants will be exercisable immediately and are exercisable for one share of our common stock. The purchase price of each pre-funded warrant is equal to the public offering price at which a share of common stock is sold to the public in this offering, minus$0.0001, and the exercise price of each pre-funded warrant is $0.0001 per share of common stock. This prospectus also relates tothe offering of the shares of common stock issuable upon exercise of the pre-funded warrants. Our common stock is listed on the Nasdaq Capital Market under the symbol “CRBP.” On October 29, 2025, the last reported salesprice of our common stock on the Nasdaq Capital Market was $16.86 per share. There is no established public trading market forthe pre-funded warrants, and we do not expect a market to develop. In addition, we do not intend to apply for listing of the pre-funded warrants on any securities exchange or recognized trading system. Investing in our common stock involves risks. Before buying any shares, you should read the discussion of material risks ofinvesting in our common stock in “Risk Factors” beginning on page S-9of this prospectus supplement, on page4of theaccompanying prospectus and in the documents incorporated by reference in this prospectus supplement. Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of thesesecurities or determined if this prospectus is truthful or complete. Any representation to the contrary is a criminal offense. (1) We have agreed to reimburse the underwriters for certain of their reasonable out-of-pocket expenses. See “Underwriting”beginning on page S-18for more information on this offering and the underwriting arrangements. Delivery of the shares of common stock is expected to be made on or about October, 2025. We have granted the underwriters anoption for a period of 30 days to purchase up toadditional shares of our common stock. If the underwriters exercise the optionin full, the total underwriting discounts and commissions payable by us will be $and the total proceeds to us, before expenses,will be $. Joint book-running managers Jefferies Piper Sandler The date of this prospectus supplement is October, 2025 TABLE OF CONTENTS PROSPECTUS SUPPLEMENT PageABOUT THIS PROSPECTUS SUPPLEMENTS-1SUMMARYS-3THE OFFERINGS-7RISK FACTORSS-9SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTSS-11USE OF PROCEEDSS-13DILUTIONS-14DESCRIPTION OF SECURITIES WE ARE OFFERINGS-16UNDERWRITINGS-18LEGAL MATTERSS-27EXPERTSS-28ADDITIONAL INFORMATIONS-29INCORPORATION OF CERTAIN INFORMATION BY REFERENCES-30 PROSPECTUS ABOUT THIS PROSPECTUS1PROSPECTUS SUMMARY2RISK FACTORS4FORWARD-LOOKING STATEMENTS5USE OF PROCEEDS6THE SECURITIES WE MAY OFFER7DESCRIPTION OF CAPITAL STOCK8DESCRIPTION OF STOCK WARRANTS11DESCRIPTION OF DEBT SECURITIES13DESCRIPTION OF SUBSCRIPTION RIGHTS19DESCRIPTION OF UNITS20FORMS OF SECURITIES21PLAN OF DISTRIBUTION23LEGAL MATTERS27EXPERTS28DISCLOSURE OF COMMISSION POSITIONON INDEMNIFICATION FOR SECURITIES ACT LIABILITIES29ADDITIONAL INFORMATION30INCORPORATION OF CERTAIN INFORMATION BY REFERENCE31 This document is in two parts. The first part is this prospectus supplement, which describes the terms of this offering of commonstock and also adds to and updates information contained in the accompanying prospectus and the documents incorporated byreference into this prospectus supplement and the accompanying prospectus. The second part, the accompanying prospectus datedMarch 20, 2024, including the documents incorporated by reference therein, provides more general information. Generally, whenwe refer to this prospectus, we are referring to both parts of this document combined. To the extent there is a conflict between theinformation contained in this prospectus supplement, on the one hand, and the information contained in the accompanyingprospectus or in any document incorporated by reference that was filed with the Securities and Exchange Commission, or the SEC,before the date of this prospectus supplement, on the other hand, you should rely on the information in this prospectus supplement.If any statement in one of these documents is inconsistent with a statement in another document having a later date — for example,a document incorporated by reference in the accompanying prospectus — th